CD274 and neoplasm: Sub-analyses of trials employing immunotherapy combinations (anti-PDL1 + anti-CTL4 or anti-PDL1 + targeted therapy) in patients with MSS metastatic CRC suggest that the density of TILs could serve as a more reliable prognostic biomarker for treatment efficacy compared to tumour mutational burden [29–32].